Q&A
MSK's approach to treating rare and common cancers
1:18:17
·
76 sec
Council Member Lynn Schulman inquires about MSK's reputation for treating difficult cases. Dr. Jeffrey Drebin explains that while MSK does treat rare cancers, they also handle common cancers with better outcomes than national averages across all stages.
- MSK treats both rare and common types of cancer
- Outcomes at MSK are better than national averages for all stages of cancer
- Dr. Drebin emphasizes MSK's commitment to disseminating their knowledge and improving cancer care broadly
Lynn Schulman
1:18:17
So my understanding of MSK, I'm not I haven't been impatient there, but my understanding of MSK is that you actually treat cancers that is somewhat untreatable in other places.
1:18:28
And
Jeffrey Drebin
1:18:29
So so, yeah, that rare cancers, I should say.
1:18:31
There is truth to the fact that we take care of rare cancers.
1:18:34
We do more of most uncommon cancers than any even big academic center is likely to see.
1:18:41
But we also treat colon cancer, prostate cancer, breast cancer.
1:18:45
And if you look at outcomes at Memorial Sloan Kettering for stage 1 cancers, early cancers, they're better than any of the big national databases.
1:18:55
And that's true whether it's stage 1, stage 2, stage 3, or stage 4.
1:18:58
So, yes, advanced cancers do better under our Four walls.
1:19:02
Rare cancers do better, but so do breast cancers, so do colon cancer, so does every other type of cancer, And and we would you know, there are 2 things.
1:19:11
Number 1, we like to make that available as much as we can.
1:19:14
And number 2, we don't keep any trade secrets.
1:19:17
Everything we do, we try to publish clinical trials and bring those to the community.
1:19:22
We think because we're dedicated to this one mission, we're doing today what others will do in a few years, but we hope that we'll disseminate what we learn and that everyone will be able to get that kind of care down the road.
Lynn Schulman
1:19:34
So I have a question.